Medicine Prices in India
India produces 20% of the world's generic medicines. Explore research-based price comparisons, understand the pharmaceutical landscape, and learn why the same drugs cost a fraction of US or UK prices.
Educational content only. This is not medical advice. Prices are approximate, based on published research and public data. Always consult a licensed healthcare professional before making medication decisions.
Filter by Category
Denosumab
RANKL Inhibitor (Monoclonal Antibody)
India
$60 – $150
US
$1,800 – $2,500
UK
$400 – $800
Difamilast
Phosphodiesterase-4 (PDE4) Inhibitor (Topical)
India
$5 – $15
US
$500 – $800
UK
$150 – $300
Hydroxychloroquine Sulfate
Autophagy Inhibitor / Antimalarial (Repurposed for Oncology)
India
$4 – $7
US
$45 – $120
UK
$15 – $40
Icotrokinra
IL-19 Targeted Biologic
India
$150 – $400
US
$5,000 – $8,000
UK
$2,000 – $4,000
Insulin Glargine
Long-Acting Basal Insulin Analog
India
$12 – $25
US
$300 – $450
UK
$80 – $130
Orforglipron (GLP-1 Receptor Agonist)
Non-Peptide GLP-1 Receptor Agonist
India
$15 – $45
US
$149 – $349
UK
$120 – $280
Paracetamol (Acetaminophen)
Analgesic / Antipyretic (Non-opioid)
India
₹10 – ₹45
US
$5 – $12
UK
£1 – £5
Semaglutide
GLP-1 Receptor Agonist (Peptide)
India
$25 – $50
US
$800 – $1,350
UK
$250 – $400
Trastuzumab
HER2-Targeted Monoclonal Antibody
India
$200 – $500
US
$4,500 – $6,000
UK
$1,500 – $3,000
Vepdegestrant
Heterobifunctional Protein Degrader (ER Degrader)
India
$800 – $1,500
US
$12,000 – $18,000
UK
$8,000 – $12,000
No medicines match this filter.
Drug Price Comparison — India vs US vs UK
Approximate prices per month supply. Based on publicly available pricing data.
| Medicine | Category | India | US | UK | Difference |
|---|---|---|---|---|---|
| Denosumab RANKL Inhibitor (Monoclonal Antibody) | Other | $60 – $150 | $1,800 – $2,500 | $400 – $800 | ~97% |
| Difamilast Phosphodiesterase-4 (PDE4) Inhibitor (Topical) | Dermatological | $5 – $15 | $500 – $800 | $150 – $300 | ~99% |
| Hydroxychloroquine Sulfate Autophagy Inhibitor / Antimalarial (Repurposed for Oncology) | Oncology | $4 – $7 | $45 – $120 | $15 – $40 | ~91% |
| Icotrokinra IL-19 Targeted Biologic | Dermatological | $150 – $400 | $5,000 – $8,000 | $2,000 – $4,000 | ~97% |
| Insulin Glargine Long-Acting Basal Insulin Analog | Diabetes | $12 – $25 | $300 – $450 | $80 – $130 | ~96% |
| Orforglipron (GLP-1 Receptor Agonist) Non-Peptide GLP-1 Receptor Agonist | Diabetes | $15 – $45 | $149 – $349 | $120 – $280 | ~90% |
| Paracetamol (Acetaminophen) Analgesic / Antipyretic (Non-opioid) | Pain & Inflammation | ₹10 – ₹45 | $5 – $12 | £1 – £5 | ~100% |
| Semaglutide GLP-1 Receptor Agonist (Peptide) | Diabetes | $25 – $50 | $800 – $1,350 | $250 – $400 | ~97% |
| Trastuzumab HER2-Targeted Monoclonal Antibody | Oncology | $200 – $500 | $4,500 – $6,000 | $1,500 – $3,000 | ~96% |
| Vepdegestrant Heterobifunctional Protein Degrader (ER Degrader) | Oncology | $800 – $1,500 | $12,000 – $18,000 | $8,000 – $12,000 | ~93% |
Frequently Asked Questions
Understanding India's pharmaceutical landscape.
1 Why are medicines so cheap in India?
India is the world's largest producer of generic medicines. The Indian Patents Act allows compulsory licensing, Indian pharma companies have lower manufacturing costs, and the government regulates drug prices through the National Pharmaceutical Pricing Authority (NPPA). Over 60% of the world's vaccines and 20% of all generic drugs come from India.
2 Are generic medicines from India FDA-approved?
Many Indian pharmaceutical companies are approved by the US FDA, UK MHRA, and WHO. Companies like Sun Pharma, Cipla, Dr. Reddy's, and Lupin export to over 200 countries. However, not every brand or formulation sold in India has US FDA approval — the regulatory landscape varies by product.
3 What is the difference between generic and branded drugs?
Generic drugs contain the same active ingredient, dosage, and form as the branded original. They must demonstrate bioequivalence — meaning they work the same way in the body. The price difference exists because generic manufacturers don't bear the original R&D costs and face market competition.
4 How does India regulate drug prices?
India's National Pharmaceutical Pricing Authority (NPPA) controls prices of essential medicines under the Drug Price Control Order (DPCO). The National List of Essential Medicines (NLEM) covers 300+ drugs with price caps. Additionally, the Jan Aushadhi scheme provides quality generics at 50-90% lower prices through government pharmacies.
5 What are biosimilars and why is India a leader?
Biosimilars are near-identical copies of biologic drugs (complex protein-based medicines). India was among the first countries to establish biosimilar guidelines (2012) and is a major manufacturer. Indian biosimilars for drugs like Trastuzumab, Rituximab, and Adalimumab are exported globally and approved by WHO, EMA, and other regulators.
Planning a medical trip to India?
We help international patients connect with accredited hospitals. Send us your requirements and get guidance within 48 hours — completely free.